A Novel Series of (S)-2,7-Substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor .ALPHA./.GAMMA. Dual Agonists with Protein-Tyrosine Phosphatase 1B Inhibitory Activity
作者:Kazuya Otake、Satoru Azukizawa、Masaki Fukui、Michiko Shibabayashi、Hikaru Kamemoto、Tomohiro Miike、Kazuyoshi Kunishiro、Masayasu Kasai、Hiroaki Shirahase
DOI:10.1248/cpb.59.1233
日期:——
Novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and (S)-7-(2-2-[(E)-2-cyclopentylvinyl]-5-methyloxazol-4-yl}ethoxy)-2-[(2E,4E)-hexadienoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (14c) was identified as a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist. The transactivation activity of 14c was comparable to that of rosiglitazone in human PPARγ (EC50=0.14 μM) and was much higher than in human PPARα (EC50=0.20 μM). In addition, 14c, but not rosiglitazone, showed human protein-tyrosine phosphatase 1B (PTP-1B) inhibitory activity (IC50=1.85 μM). 14c showed about 10-fold stronger hypoglycemic and hypotriglyceridemic effects than rosiglitazone by repeated application for 14 d in male KK-Ay mice. Furthermore, 14c, but not rosiglitazone, increased hepatic peroxisome acyl CoA oxidase activity at 30 mg/kg/d for 7 d in male Syrian hamsters, probably due to its PPARα agonist activity. 14c did not affect plasma volume at 100 mg/kg/d for 14 d in male ICR mice, while rosiglitazone significantly increased it. In conclusion, 14c is a promising candidate for an efficacious and safe anti-diabetic drug with triple actions as a PPARα/γ dual agonist with PTP-1B inhibitory activity.
合成了新型1,2,3,4-四氢异喹啉-3-羧酸衍生物,并鉴定出(S)-7-(2-2-[(E)-2-环戊基乙烯]-5-甲氧基噁唑-4-基}乙氧基)-2-[(2E,4E)-己二烯酰]-1,2,3,4-四氢异喹啉-3-羧酸(14c)作为过氧化物酶体增殖物激活受体(PPAR)α/γ双重激动剂。14c的转激活活性与人类PPARγ的罗格列酮相当(EC50=0.14 μM),而在PPARα中的活性则明显高于罗格列酮(EC50=0.20 μM)。此外,14c显示出对人类蛋白酪氨酸磷酸酶1B(PTP-1B)的抑制活性(IC50=1.85 μM),而罗格列酮则没有。14c在对雄性KK-Ay小鼠进行14天的重复给药中,显示出比罗格列酮强约10倍的降血糖及降低甘油三酯效果。此外,14c在雄性叙利亚仓鼠中以30 mg/kg/d剂量连续7天应用时,增加了肝脏过氧化物酶体酰基辅酶A氧化酶的活性,这可能与其PPARα激动剂活性有关。而14c在雄性ICR小鼠的100 mg/kg/d剂量下连续14天的实验中未对血浆体积产生影响,而罗格列酮则显著增加了血浆体积。总之,14c作为一种PPARα/γ双重激动剂并具有PTP-1B抑制活性,是一种有前景的有效且安全的抗糖尿病药物候选者。